Company Description
Generic drugs are Taro's future. Taro Pharmaceutical Industries makes generic and proprietary drugs and OTC products used to treat skin conditions,...
Headquarters:
Euro Pk., Italy Bldg., Yakum Business Pk.Yakum, 60972, Israel
Key Taro Financials
| Company Type | Public - Pink Sheets: TAROF Main Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2004 Employees | 1,347 |
More Taro Financials (10 pages)
Competition
Competitive Landscape for Pharmaceutical Manufacture and Sale
The industry is marked by rapid advances in scientific knowledge that produce ever-more effective medicines. Profitability is determined mainly by the ability to discover new drugs....
Read more about Taro's competition across multiple industries
Top Taro Competitors
Sponsored Links
The Business DirectoryTrading Toolbox
Taro Executives sponsored by genius.com
| Title | Name & Bio | Contact |
|---|---|---|
| Chairman | Barrie Levitt | Network | E-mail |
| Group VP, Sales and Marketing; Deputy General Manager, Israel | Zahava Rafalowicz | Network | E-mail |
| VP Information Technology, Israel | Tzvi Tal | Network | E-mail |
| Are You Listed On Hoover's? | ||
|---|---|---|
| Hoover's subscribers also get access to information on people who have self-listed with this company. Subscribers also have the option to add themselves to this company record. |
Current Taro News
- Taro advises investors to hold off Sun offer: The offer is aimed primarily at buying Taro's founders shares. [Globes (Tel Aviv)] (01 Jul 2008 04:00:00 EDT)
- Sun demands Taro founders' shares at original deal price: Under the option agreement, Sun will acquire Taro's founding shares at $7.75 per share, compared with its current market price of $9.50. [Globes (Tel Aviv)] (26 Jun 2008 04:00:00 EDT)
- Taro sues Sun and warns investors of revised offer: Barrie Levitt: Our board strongly recommends that you not take any hasty action with respect to your shares. [Globes (Tel Aviv)] (19 Jun 2008 04:00:00 EDT)
Latest Industry Video
-
Rx For Cheap Drugs (4:04)
07/23/07 5:20PM ET - Miller Tabak & Co. Pharmaceuticals Analyst Les Fundleyder and Bain & Company Partner Tim Van Biesen discuss patent expirations affecting U.S. drug costs.







